Nuklearmedizin 1986; 25(05): 181-187
DOI: 10.1055/s-0038-1624339
Originalarbeiten - Original Articles
Schattauer GmbH

Long-Term Clinical Investigation of the Hepatobiliary Agents: 99mTc- HIDA and 99mTC-p-Butyl-IDA

N. H. Agha
1   From the Nuclear Research Centre, Radioisotope Production Department, Baghdad, College of Medicine, Al-Mustanserria University, Baghdad, Iraq
,
A. M. AI-Hilli
1   From the Nuclear Research Centre, Radioisotope Production Department, Baghdad, College of Medicine, Al-Mustanserria University, Baghdad, Iraq
,
N. D. Dahir
1   From the Nuclear Research Centre, Radioisotope Production Department, Baghdad, College of Medicine, Al-Mustanserria University, Baghdad, Iraq
,
M. S. Al-Hissoni
*   From the Nuclear Research Centre, Radioisotope Production Department, Baghdad, and the Department of Nuclear Medicine, College of Medicine, Al-Mustanserria University, Baghdad, Iraq
,
M. N. Jasim
*   From the Nuclear Research Centre, Radioisotope Production Department, Baghdad, and the Department of Nuclear Medicine, College of Medicine, Al-Mustanserria University, Baghdad, Iraq
,
K. M. Miran
*   From the Nuclear Research Centre, Radioisotope Production Department, Baghdad, and the Department of Nuclear Medicine, College of Medicine, Al-Mustanserria University, Baghdad, Iraq
,
H. Shubber Amira
**   From the Ebin Al-Nafees Hospital for Cardiovascular Diseases and Yarmouk Teaching Hospital, College of Medicine, Al-Mustanserria University, Baghdad, Iraq
› Author Affiliations
The authors would like to thank Mr. H. M. A. Karim for his technical assistance and Mr. J. A. Razzak for typing the manuscript. This work was performed under the auspices of the Iraqi Atomic Energy Commission. This paper has been presented in part at the European Nuclear Medicine Congress, Helsinki, August 1984
Further Information

Publication History

Received: 14 January 1986

Publication Date:
12 January 2018 (online)

The organ distribution data for the two hepatobiliary agents HIDA and p-butyl- IDA in mice showed substantial differences in the extent and rate of hepatobiliary clearance of radioactivity. 99mTc-HIDA and 99mTc-p-butyl-IDA were used in computer assisted serial hepatobiliary scintigraphy. In normal subjects, the data of dynamic studies showed that the kidneys were no longer seen after 2.5 min with p-butyl-IDA. Liver radioactivity decreased significantly after 10 min with HIDA compared to 35 min with p-butyl-IDA. The gall bladder was always visualized at the 10-12th min and the 25-30th min with HIDA and p-butyl-IDA respectively. 99mTc-HIDA provided superior hepatic duct images.

Zusammenfassung

Die Organverteilung der beiden hepatobiliären Agenzien HIDA und p-butyl-IDA wiesen bei der Maus erhebliche Unterschiede in Ausmaß und Schnelligkeit der hepatobiliären Radioaktivitätsclearance auf. 99mTc- HIDA und 99mTc-p-butyl-IDA wurden für die computerunterstützte hepatobiliäre Sequenzszintigraphie eingesetzt. Bei Normalpersonen zeigte die dynamische Studie, daß die Nieren mit p-butyl-IDA nach 2.5 min nicht mehr sichtbar waren. Die Radioaktivität in Leberparenchymen nahm signifikant ab der 10, min bei HIDA und ab der 35. min bei p-butyl-IDA ab. Die Gallenblase wurde immer zwischen der 10.-12. min und 25.-30. min mit HIDA bzw. p-butyl- IDA dargestellt. Eine bessere Darstellung der Gallenwege war mit 99mTc-HIDA gewährleistet.

revised form: April 25, 1986

 
  • REFERENCES

  • 1 Chervu L. R, Num A. D, Loberg M. D. Radiopharmaceuticals for hepatobiliary imaging. Sem. nucl. Med 1982; 12: 5-17.
  • 2 Collier B. D, Treves S, Davis M. A. et al. Simultaneous 99mTc-p-butyl-IDA and 131I-Rose bengal scintigraphy in neonatal jaundice. Radiology 1980; 134: 719-22.
  • 3 Edlund G, Kempi V, Linden W. Transient nonvisualization of the gall bladder by 99mTc-HIDA cholescintigraphy in acute pancreatitis. J. nucl. Med 1982; 23: 117-20.
  • 4 Freitas J. E. Cholescintigraphy in acute and chronic cholecystitis. Sem. nucl. Med 1982; 12: 18-26.
  • 5 Harvey E, Loberg M, Ryan J. et al. Hepatic clearance mechanism of 99mTc- HIDA and its effect on quantitation of hepatobiliary function. J nucl. Med 1979; 20: 310-3.
  • 6 Loberg M. D, Cooper M, Harvey E. et al. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. J. nucl. Med 1976; 17: 633-8.
  • 7 Molter M, Kloss G. Properties of various IDA derivatives. J. labell. Comp. Radiopharm 1981; 18: 56-7.
  • 8 Nunn A. D. Preliminary structure-distribution relationships (SDRs) of 99mTchepatobiliary agents. (1) Protein binding of HIDAs. J. labell. Comp. Radiopharm 1981; 18: 155-6.
  • 9 Persson R. B. R, Strand S. E. In: Radiopharmaceuticals and Labeled Compounds. Vol. I, 169 IAEA; Vienna: 1973
  • 10 Persson R. B. R. Proc. Int. Symp. Radiopharmaceuticals, Atlanta, Ga. 1974: 228 Soc. nucl. Med. New York: 1975
  • 11 Popescu H. I. Hepatic clearance mechanism of 99mTc-N-(Acetanilido)-iminodiacetic acid derivatives. J. nucl. Med 1980; 21: 1110.
  • 12 Rosenthall L, Shaffer E. A, Lisbona R, Pare P. Diagnosis of hepatobiliary disease by 99mTc - HIDA cholescintigraphy. Radiology 1978; 126: 467-74.
  • 13 Rosenthall L, Fonseca C, Arzoumanian A. et al. 99mTc-IDA hepatobiliary imaging following upper abdominal surgery. Radiology 1979; 130: 737-9.
  • 14 Ryan J, Copper M, Loberg M. et al. Technetium-99m-labeled N-(2,6-dimethylphenylcarbamoyl methyl) iminodiacetic acid (99mTc-HIDA): A new radiopharmaceutical for hepatobiliary imaging studies. J. nucl. Med 1977; 18: 977-1004.
  • 15 Wistow B. W, Subramanian G, Van Heertom R. L. et al. An evaluation of 9y99mTc-labelcd hepatobiliary agents. nucl. Med 1977; 18: 455-61.
  • 16 Wistow B. W, Subramanian G, Gagne M. et al. Experimental and clinical trials of new WmTc-labeIed hepatobiliary agents. Radiology 1978; 128: 793-4.